Niraparib
- Generic Name
- Niraparib
- Brand Names
- Zejula
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O
- CAS Number
- 1038915-60-4
- Unique Ingredient Identifier
- HMC2H89N35
- Background
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
- Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
- Associated Therapies
- Maintenance therapy
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04592237
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT04584255
- Locations
- 🇺🇸
Yale University Cancer Center, New Haven, Connecticut, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 136
- Registration Number
- NCT04577833
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇵🇱Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warszawa, Poland
🇫🇷HIA Begin, Saint Mande, France
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Xiaoxiang Chen
- Target Recruit Count
- 32
- Registration Number
- NCT04556071
- Locations
- 🇨🇳
JiangSu Cancer Hospital, Nanjing, Jiangsu, China
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 316
- Registration Number
- NCT04546373
- Locations
- 🇪🇸
Hospital Universitari Dexeus - Grupo Quirónsalud, Barcelona, Spain
🇪🇸Institut Català d´ Oncologia-Hospital Duran y Reynals, L'Hospitalet De Llobregat, Barcelona, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT04544995
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT04507841
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 696
- Registration Number
- NCT04497844
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Houston Metro Urology, Houston, Texas, United States
🇧🇪Jolimont, Haine-St-Paul, Belgium
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT04493060
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 666
- Registration Number
- NCT04475939
- Locations
- 🇬🇧
GSK Investigational Site, Wrexham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.